HNSBF News and Press, Hansa Biopharma AB From 05/13/20

LUND, Sweden , May 13, 2020 /PRNewswire/ -- Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the Company's management team will participate in the following upcoming investor conferences: UBS Global Healthcare Confe...

LUND, Sweden , April 28, 2020 /PRNewswire/ -- Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and interim report for the first quarter 2020. Highlights for the first quarter 2020 The ongoing ...

LUND, Sweden , April 15, 2020 /PRNewswire/ -- Hansa Biopharma will publish its interim report for January- March 2020 at 8:00 a.m. CET on April 28, 2020 . All interested parties are invited to participate in a telephone conference, which will include a presentation of the interim resu...

LUND, Sweden , March 6, 2020 /PRNewswire/ -- Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases today announced that two posters sessions were hightlighted at the Cutting Edge of Transplantation summit 2020, Thursday March 5 th . A poster ...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

LUND, Sweden , Feb. 25, 2020 /PRNewswire/ --  Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the Company's management team will participate in the following upcoming investor conferences:  Cowen and Compa...

Hansa Biopharma AB ( OTC:HNSBF ): Q4 GAAP EPS of -SEK2.77. More news on: Hansa Biopharma AB (publ), Earnings news and commentary, Read more ...

LUND, Sweden , Jan. 27, 2020 /PRNewswire/ -- Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the patient enrollment in an investigator-initiated phase 2 study to evaluate safety, tolerability and efficacy of imlif...

LUND, Sweden , Jan. 22, 2020 /PRNewswire/ -- Hansa Biopharma will publish its Year-End report 2019 at 8:00 a.m. CET on February 6, 2020 . All interested parties are invited to participate in a telephone conference, which will include a presentation of the interim results and a business...

LUND, Sweden , Jan. 13, 2020 /PRNewswire/ --  Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced a business update for the fourth quarter 2019 and preliminary, unaudited key financials for its financial year 2019.  ...